EHA 2022 – Crispr still looks bloody good
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
EHA 2022 preview – some good news at last
Positive data result in positive share price movements – something of a novelty in the current market.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Intellia’s in vivo Crispr stays in play, clinically at least
Though broad questions intensify, NTLA-2001 continues showing clinically what it is meant to.
